Remibrutinib
- Generic Name
- Remibrutinib
- Drug Type
- Small Molecule
- Chemical Formula
- C27H27F2N5O3
- CAS Number
- 1787294-07-8
- Unique Ingredient Identifier
- I7MVZ8HDNU
A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 71
- Registration Number
- NCT05048342
- Locations
- 🇯🇵
Novartis Investigative Site, Osaka, Japan
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 229
- Registration Number
- NCT04109313
- Locations
- 🇬🇧
Novartis Investigative Site, Plymouth, United Kingdom
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 73
- Registration Number
- NCT04035668
- Locations
- 🇬🇧
Novartis Investigative Site, Tyne And Wear, United Kingdom
Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064
Phase 1
Completed
- Conditions
- Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 185
- Registration Number
- NCT03918980
- Locations
- 🇳🇱
Novartis Investigative Site, Leiden, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath